Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Travere TherapeuticsTVTX +1.96%61 Median PS Value is $37.48 as of Aug. 22, 2026, which is 4208% above its 10-year median of 0.87. GuruFocus rates TVTX with a GF Score™ of 61/100 and a GF Value™ of $36.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 281 Biotechnology companies, Travere Therapeutics ranks worse than 86.83% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Travere Therapeutics (NAS:TVTX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Travere Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
65.705
/
37.48
=
1.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics Median PS Value Related Terms
Travere Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for Travere Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TVTX vs ORKA, DNTH, SRRK: Median PS Value Comparison
For the Biotechnology subindustry, Travere Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Travere Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.0045.
Travere Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.242.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics (TVTX) has a Median PS Value of $37.48 as of Aug. 22, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Travere Therapeutics and its competitors. This is 4208% above median its historical median of 0.87. Over the past decade, Travere Therapeutics' Median PS Value has ranged from 0.58 to 1.76. According to the industry distribution chart, Travere Therapeutics ranks #244 out of 281 companies in the Biotechnology industry, placing it in the top 86.8%.
Is Travere Therapeutics' Median PS Value too high?
Travere Therapeutics' current Median PS Value of $37.48 is 4208% above median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 1.76. The Biotechnology industry median Median PS Value is 0.63. Travere Therapeutics' value of $37.48 is 5849.2% above this industry median. Based on the distribution chart, Travere Therapeutics ranks #244 out of 281 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Median PS Value compare to ORKA and DNTH?
According to the Biotechnology industry distribution chart, Travere Therapeutics ranks #244 out of 281 companies for Median PS Value. This places Travere Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.63. Travere Therapeutics' value of $37.48 is 5849.2% above this benchmark. Historically, Travere Therapeutics' own Median PS Value has ranged from 0.58 to 1.76 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 0.63, Travere Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Travere Therapeutics's current Median PS Value of $37.48 is 5849.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Travere Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Travere Therapeutics's current Median PS Value is $37.48, which is 4208% above median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Median PS Value is $37.48, which is 4208% above median its 10-year median of 0.87 and 5849.2% above the Biotechnology industry median of 0.63. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Median PS Value is $37.48 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Travere Therapeutics (TVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued.
The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75.
GuruFocus considers Travere Therapeutics to be Significantly Overvalued.
Key valuation signals for TVTX:
Median PS Value: $37.48 (4208% above median its 10-year median of 0.87)
GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
Industry Position: 5849.2% above the Biotechnology median (#244 of 281)
No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score
Get the complete analysis for TVTX
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TVTX has been successfully added to your 
